Results of phase III DEVENT trial show improved survival outcomes with ruxolitinib in U.S. participants

Ruxolitinib is a JAK1/2 inhibitor currently approved for the treatment of myelofibrosis,...

NCCN COVID-19 vaccination recommendations for patients with hematologic malignancies

Patients with cancer are at high risk of COVID-19-associated complications and, accordingly, the preliminary...

What needs to be considered in patients with MPN with COVID-19?

During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We...

Essential thrombocythemia is associated with a higher risk of thrombosis during COVID-19

COVID-19 has been reported to damage multiple organ systems, primarily the respiratory system, which...

What is the impact of pre-treatment ruxolitinib on patients with MF receiving allo-HSCT? An EBMT CMWP study

Most patients (89%) diagnosed with myelofibrosis (MF) present with splenomegaly, and new or...

Editorial Theme | The management of relapsed/refractory myelofibrosis: Part 4 – investigational combination approaches

The unmet clinical need in treating patients with relapsed or refractory...

Should patients with myelofibrosis be transplanted before or after ruxolitinib failure?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the MPN Hub...

Reviewing the safety of JAK inhibitors for the treatment of myelofibrosis

Over the past decade, seminal studies have led to the identification of specific driver mutations in the pathogenesis of...

5-year results from the PROUD-PV and CONTINUATION-PV studies

Ropeginterferon alfa-2b is a novel pegylated recombinant interferon, approved in the EU as monotherapy for the treatment of adults with...

ASH 2020: Highlights for polycythemia vera

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Tiziano Barbui, Papa Giovanni XXIII Hospital,...

Interferon therapy in the management of myeloproliferative neoplasms

Treatment with interferon (IFN) therapy is considered successful for patients with myeloproliferative neoplasms (MPN), such as...

Ropeginterferon alfa-2b is effective and safe in patients older than 60 years with PV

As discussed in our last editorial theme, the pegylated forms of interferon-alpha improve treatment compliance...